admin

Close up of lab assistant in uniform, with mask and rubber gloves holding test tube with blood sample while sitting on chair and typing on laptop. Selective focus on test tubes.

FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE

Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™ Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials TOKYO and CAMBRIDGE, Mass., Jan. 6, …

FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE Read More »

researcher using microscope parkinson's case study

EISAI’S COMMITMENT TO SCIENTIFIC EVIDENCE AND PATIENT

TOKYO, Jan. 6, 2023 /PRNewswire/ — LEQEMBI™ (lecanemab-rimb) has the potential to make a difference for people living with early Alzheimer’s disease (AD), their loved ones and healthcare professionals, and was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD. Eisai has worked with the FDA and the FDA has approved …

EISAI’S COMMITMENT TO SCIENTIFIC EVIDENCE AND PATIENT Read More »

brown haired smiling woman bradenton research center

WE’RE FINDING NEW WAYS TO TREAT MULTIPLE SCLEROSIS

Multiple Sclerosis is a long-term illness where the body’s immune system attacks and damages the protective covering, called myelin, around the nerves in the central nervous system. People with relapsing MS will have repeated attacks, known as relapses, and we’re finding new ways to stop them. People with MS can experience a variety of symptoms, …

WE’RE FINDING NEW WAYS TO TREAT MULTIPLE SCLEROSIS Read More »